Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)PRNewsWire • 08/30/23
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 08/28/23
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesPRNewsWire • 08/01/23
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of DirectorsPRNewsWire • 07/24/23
Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq RulesPRNewsWire • 07/14/23
Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq RulesPRNewsWire • 07/12/23
Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in BostonPRNewsWire • 06/01/23
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor ConferencePRNewsWire • 05/09/23
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient PopulationPRNewsWire • 03/09/23
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023PRNewsWire • 02/08/23
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public OfferingPRNewsWire • 01/24/23
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial FibrillationPRNewsWire • 01/23/23